

Reference:	FOI.3747.20
Subject:	Atopic dermatitis treatments
Date of Request:	3 August 2020

Requested:

1. How many patients were treated within your Trust with the following drugs within the specified time periods?

Drug	Number of patients treated between 01 February 2017 and 31 July 2018	Number of patients treated between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		

2. How many patients were treated within your Trust for atopic dermatitis within the specified time periods?

Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020

3. How many patients were treated within your Trust with the following drugs for atopic dermatitis within the specified time periods?

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		

4. Please specify how patients treated with the following drugs are coded (OPCS code) within your trust:

Drug	OPCS code (e.g. X385 subcutaneous immunotherapy)
Apremilast	
Adalimumab	
Dupilumab	
Etanercept	
Infliximab	
Secukinumab	
Ustekinumab	

5. Please provide the number of patients treated in the homecare setting for atopic dermatitis within the specified time periods:

Number of patients treated in the homecare setting for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated in the homecare setting for atopic dermatitis between 01 August 2018 and 31 January 2020

6. How many of your Trust's homecare patients were treated with the following drugs for atopic dermatitis within the specified time periods?

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for questions 2, 3, 5 and 6, as it is estimated that the cost of answering your request would exceed the “appropriate level” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. The “appropriate level” represents the estimated cost of one person spending 18 hours or (2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the requested information, the UHB would need to undertake a manual trawl of all patient records, to identify any information that fulfils your request.

Therefore, for questions 2, 3, 5 and 6, the UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000, which provides an exemption from a public authority's obligation to comply with a request for information, where the cost of compliance is estimated to exceed the appropriate limit.

1. The UHB provides, within the table below, the number of patients that were treated with the drugs listed for the periods requested.

Drug	Number of patients treated between 01 February 2017 and 31 July 2018	Number of patients treated between 01 August 2018 and 31 January 2020
Apremilast	9	5
Adalimumab	286	148
Dupilumab	*	25
Etanercept	289	132
Infliximab	201	99
Secukinumab	42	43
Ustekinumab	53	45

4. The UHB provides, within the table below, the OPCS Classification of Interventions Procedures codes, the procedural classification used within the NHS, for the listed drugs requested.

Drug	OPCS code (e.g. X385 subcutaneous immunotherapy)	
	Pre April 2020	Post April 2020
Apremilast	X92.1	X38.5
Adalimumab	X92.1	X38.5
Dupilumab	Not applicable	X38.5
Etanercept	X92.1	X38.5
Infliximab	X92.1	X29.2
Secukinumab	X92.1	X38.5
Ustekinumab	X89.1	X38.5

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/ General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.